Our data indicated that patients with higher expression of DDX3X/CBS, DDX3X/METTL16 and DDX3X/JUND exhibited poorer overall survival and progression-free interval (Fig. S8A–F), suggesting the prognostic value of DDX3X and its associated genes for lung cancer patients. Here, METTL16 is linked to lung carcinoma.